Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 3/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906082 | 0.87 | MAPT (0.42) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL4145756 | 0.87 | REN (0.38) | MAPTRENCYP3A4THRBTP53 | |
| SCHEMBL4538962 | 0.85 | MAPT (0.40) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL1036573 | 0.85 | MAPT (0.41) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL3919417 | 0.85 | MAPT (0.41) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL4647385 | 0.85 | MAPT (0.41) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL3911082 | 0.82 | MAPT (0.40) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL1036571 | 0.81 | MAPT (0.41) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL3916024 | 0.80 | TP53 (0.38) | MAPTTSHRRENSMPD1CYP3A4 | |
| SCHEMBL3908343 | 0.80 | MAPT (0.42) | MAPTTSHRRENSMPD1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1973903-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | Speedel Experimenta AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007082907-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | REN, AGTR2, ACE | MAPT 3262/4885TSHR 1026/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.